ArticleAmerican journal of hematology2021

Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.

Neha Mehta-Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.